Asked by: Maggie Throup (Conservative - Erewash)
Question to the Foreign, Commonwealth & Development Office:
To ask the Minister of State, Foreign, Commonwealth and Development Office, whether his Department plans to (a) maintain and (b) increase funding for Product Development Partnerships.
Answered by Andrew Mitchell - Minister of State (Foreign, Commonwealth and Development Office) (Minister for Development)
The Foreign Commonwealth and Development Office (FCDO) remains committed to investing in Product Development Partnerships and other global health Research and Development organisations. We plan to launch a call for proposals for funding the development of products and technologies to combat diseases of poverty, for use in Low and Lower Middle Income Countries.
At this stage, FCDO plans to invest approximately £230 million in new funding for product development research for health over a 3 - 4 year period from 2023/24.
Asked by: Maggie Throup (Conservative - Erewash)
Question to the Foreign, Commonwealth & Development Office:
To ask the Minister of State, Foreign, Commonwealth and Development Office, what funding his Department provided for vaccine research and development in each of the last five years; and what he plans to provide in each of the next five years.
Answered by Andrew Mitchell - Minister of State (Foreign, Commonwealth and Development Office) (Minister for Development)
Over the last 5 financial years (2018/19 to 2022/23) the Foreign, Commonwealth and Development Office (FCDO) have invested the following amounts in research and development for vaccines to combat diseases of poverty for use in low and lower middle-income countries:
2018/19 | 2019/20 | 2020/21 | 2021/22 | 2022/23 |
£8,528,752 | £29,589,803 | £213,773,395 | £2,391,511 | £13,012,567 |
To date, FCDO has entered into agreements to invest the following amounts on vaccine Research and Development over the next 5 financial years (2023/24 to 2027/28)*:
2023/24 | 2024/25 | 2025/26 | 2026/27 | 2027/28 |
£17,008,587 | £18,626,489 | £17,253,808 | £17,000,000 | £0 |
* The overall investment in vaccine development could increase as a result of a planned funding competition for the research and development of health products to combat diseases of poverty.
Asked by: Maggie Throup (Conservative - Erewash)
Question to the Foreign, Commonwealth & Development Office:
To ask the Secretary of State for Foreign, Commonwealth and Development Affairs, what steps his Department is taking to support the increase in bacterial vaccine manufacturing capacity in Low to Middle Income Countries.
Answered by Andrew Mitchell - Minister of State (Foreign, Commonwealth and Development Office) (Minister for Development)
The UK supports the expansion of vaccine manufacturing in low- and middle-income countries and is working with international and regional partners (including Gavi, the Coalition for Epidemic Preparedness Innovations (CEPI) and the Partnership for African Vaccine Manufacturing (PAVM)), development banks and the private sector to catalyse strategic investments for vaccine manufacturing in these countries. The UK is the second largest funder of Gavi, who are developing a strategy to support regional manufacturing capacity in low- and middle-income countries. The strategy aims to address barriers to investment in regional manufacturing and support efficient market outcomes.